Thetis Pharmaceuticals

Executive Summary

Thetis Pharmaceuticals is a clinical-stage biopharmaceutical company pioneering first-in-class oral therapeutics that harness the body's natural resolution pathways to treat inflammatory and oncologic diseases. Its lead asset, TP-317, is a stabilized oral formulation of Resolvin E1 that selectively activates the BLT1 receptor, aiming to restore immune homeostasis in inflammatory bowel disease (IBD) and to modulate the tumor microenvironment in solid tumors. Founded in 2013 and headquartered in New Haven, Connecticut, Thetis has advanced TP-317 into Phase 1 clinical trials, evaluating safety, tolerability, and pharmacokinetics in healthy volunteers and patients with IBD. The company's approach is differentiated by targeting pro-resolving mechanisms rather than conventional anti-inflammatory pathways, potentially offering improved efficacy and safety profiles. With a strong scientific foundation and an experienced management team, Thetis represents a compelling opportunity in the resolution medicine space, though it remains at an early stage with no approved products or disclosed financing rounds.

Upcoming Catalysts (preview)

• Q2 2026Phase 1 safety and pharmacokinetic data readout for TP-317 in healthy volunteers75% success
• Q4 2026Initiation of Phase 1b/2a proof-of-concept trial in inflammatory bowel disease patients60% success
• Q3 2026Presentation of preclinical data for TP-317 in solid tumor models at a major medical conference80% success